GSK Reports Promising Early Data For Experimental Cancer Drug

All NewsApril 13, 2026

GSK sees blockbuster potential for Mo-Rez after early trial data shows strong tumor reduction in hard-to-treat cancers

Importance Rank:

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.

Cookie settings ACCEPT

Manage consent